Argenx
ARGX
#439
Rank
C$72.92 B
Marketcap
C$1,171
Share price
0.06%
Change (1 day)
30.03%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): C$12.46

According to Argenx 's latest financial reports the company's current EPS (TTM) is C$12.20. In 2024 the company made an earnings per share (EPS) of C$19.14 an increase over its 2023 EPS that were of C-$7.10.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$12.46-34.91%
2024C$19.14-369.77%
2023C-$7.10-60.46%
2022C-$17.9563.33%
2021C-$10.99-40.37%
2020C-$18.43183.47%
2019C-$6.50123.09%
2018C-$2.9154.93%
2017C-$1.8814.07%
2016C-$1.6513.05%
2015C-$1.46-36.34%
2014C-$2.29209.04%
2013C-$0.74-33.99%
2012C-$1.12185.59%
2011C-$0.39